Tags

Type your tag names separated by a space and hit enter

Use of inhaled nitric oxide in the new born period: results from the European Inhaled Nitric Oxide Registry.
Acta Paediatr. 2010 Jun; 99(6):854-60.AP

Abstract

AIMS

The aim of this study was to present data relating to the use of inhaled nitric oxide (iNO) in newborn infants included in the European Inhaled Nitric Oxide Registry.

METHODS

Demographic, clinical and therapeutic data from seven European centres are reported. Univariate analyses were performed to identify factors associated with acute response to iNO and survival without extra corporeal membrane oxygenation (ECMO).

RESULTS

A total of 112 newborn infants received iNO, with 40% being less than 34 weeks gestational age. The commonest indication for iNO was secondary pulmonary hypertension. Acute response to iNO was more common in infants with a higher oxygenation index (median OI 32.7 vs 22.6, p = 0.040), although acute response did not predict survival without ECMO. Infants who survived without ECMO had a lower OI prior to therapy (median OI 24 vs 43, p = 0.009), were commenced on a higher starting dose (median dose 20 ppm vs 10 ppm p = 0.013) and received a lower maintenance dose (median dose 10 vs 17 ppm, p = 0.027) than those who died or received ECMO.

CONCLUSION

Collating and reporting data about iNO therapy in neonates across a number of European centres using a web-based system is feasible. These data may be used to monitor the clinical use of iNO, identify adverse effects, generate research hypotheses and promote high standards in the clinical use of iNO.

Links

Aggregator Full Text

Authors+Show Affiliations

Dewhurst C
Liverpool Women's Hospital, Liverpool, UK.
Ibrahim H
No affiliation info available
Göthberg S
No affiliation info available
Jónsson B
No affiliation info available
Subhedar N
No affiliation info available
European Inhaled Nitric Oxide Registry
No affiliation info available

MeSH

Administration, InhalationAnalysis of VarianceEuropeExtracorporeal Membrane OxygenationFemaleHumansInfant, NewbornInfant, PrematureInfant, Premature, DiseasesMaleNitric OxidePersistent Fetal Circulation SyndromePilot ProjectsRegistriesTreatment Outcome

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20219040

Citation

Dewhurst, Chris, et al. "Use of Inhaled Nitric Oxide in the New Born Period: Results From the European Inhaled Nitric Oxide Registry." Acta Paediatrica (Oslo, Norway : 1992), vol. 99, no. 6, 2010, pp. 854-60.
Dewhurst C, Ibrahim H, Göthberg S, et al. Use of inhaled nitric oxide in the new born period: results from the European Inhaled Nitric Oxide Registry. Acta Paediatr. 2010;99(6):854-60.
Dewhurst, C., Ibrahim, H., Göthberg, S., Jónsson, B., & Subhedar, N. (2010). Use of inhaled nitric oxide in the new born period: results from the European Inhaled Nitric Oxide Registry. Acta Paediatrica (Oslo, Norway : 1992), 99(6), 854-60. https://doi.org/10.1111/j.1651-2227.2010.01722.x
Dewhurst C, et al. Use of Inhaled Nitric Oxide in the New Born Period: Results From the European Inhaled Nitric Oxide Registry. Acta Paediatr. 2010;99(6):854-60. PubMed PMID: 20219040.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Use of inhaled nitric oxide in the new born period: results from the European Inhaled Nitric Oxide Registry. AU - Dewhurst,Chris, AU - Ibrahim,Hafis, AU - Göthberg,Sylvia, AU - Jónsson,Baldvin, AU - Subhedar,Nimish, AU - ,, Y1 - 2010/03/05/ PY - 2010/3/12/entrez PY - 2010/3/12/pubmed PY - 2010/8/18/medline SP - 854 EP - 60 JF - Acta paediatrica (Oslo, Norway : 1992) JO - Acta Paediatr VL - 99 IS - 6 N2 - AIMS: The aim of this study was to present data relating to the use of inhaled nitric oxide (iNO) in newborn infants included in the European Inhaled Nitric Oxide Registry. METHODS: Demographic, clinical and therapeutic data from seven European centres are reported. Univariate analyses were performed to identify factors associated with acute response to iNO and survival without extra corporeal membrane oxygenation (ECMO). RESULTS: A total of 112 newborn infants received iNO, with 40% being less than 34 weeks gestational age. The commonest indication for iNO was secondary pulmonary hypertension. Acute response to iNO was more common in infants with a higher oxygenation index (median OI 32.7 vs 22.6, p = 0.040), although acute response did not predict survival without ECMO. Infants who survived without ECMO had a lower OI prior to therapy (median OI 24 vs 43, p = 0.009), were commenced on a higher starting dose (median dose 20 ppm vs 10 ppm p = 0.013) and received a lower maintenance dose (median dose 10 vs 17 ppm, p = 0.027) than those who died or received ECMO. CONCLUSION: Collating and reporting data about iNO therapy in neonates across a number of European centres using a web-based system is feasible. These data may be used to monitor the clinical use of iNO, identify adverse effects, generate research hypotheses and promote high standards in the clinical use of iNO. SN - 1651-2227 UR - https://www.unboundmedicine.com/medline/citation/20219040/Use_of_inhaled_nitric_oxide_in_the_new_born_period:_results_from_the_European_Inhaled_Nitric_Oxide_Registry_ L2 - https://doi.org/10.1111/j.1651-2227.2010.01722.x DB - PRIME DP - Unbound Medicine ER -